Its administration attenuated the development of signs and symptoms of colitis, reduced colonic expression of TNF-α, Interleukin (IL)-6, and IFN-γ, and reserved colonic down-regulation of PPAR-γ, PXR, and FXR caused by a TNBS model of induced colitis [24]. This evidence concerns the gene NR1I2 and colitis.